Venturis Therapeutics Inc. Announces Granting of US Patent for the Angiogenic Treatment of Ischemic Heart Disease, issued April 6, 2021, with 15 Patent Claims

10455 Markison Rd Dallas, TX (972) 681-9368 www.VenturisTherapetuics.com April 30, 2021 Venturis Therapeutics Inc. Announces Granting of US Patent for the Angiogenic Treatment of Ischemic Heart Disease, issued April 6, 2021, with 15 Patent Claims Dallas, TX - Venturis Therapeutics, Inc. (“VT” or the “Company”) today announced the issuance of U.S. Patent No. 10,966,610 entitled “Angiogenic Treatment of Ischemic Heart Disease”. The claims in this patent are directed to: (1) a method of treating an ischemic region of the heart by non-invasively imaging the heart, and (2) using that image to guide an injection of the heart with fibroblast growth factor-1 (FGF-1), at a specified dosage, to prevent relocation of myofibrils, glycogen loss, or mitochondrial swelling, and that induces cardiac angiogenesis at the site of injection. The patent has three independent claims of varying scope. For example, the second independent claim spells out that the FGF-1 is in a carrier, while the third independent claim requires that the dose of FGF-1 induces the growth of supplemental blood vessels at the site of injection. “As a company, we are dedicated to securing intellectual property as we expand and develop our therapeutic programs . With this patent secured, and our heart trial data, we feel confident in our ability to develop and expand this program as more data is generated in our Phase 2 trials,” stated Venturis’ Chairman, President, and CEO, Calvin Wallen III. ABOUT VENTURIS THERAPEUTICS Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as diabetic wounds, se vere coronary heart disease, peripheral artery disease, erectile dysfunction, stroke, and spinal disk disease. The active pharmaceutical ingredient (“API”) in our drug candidates is FGF-1, a human protein that stimulates the growth of new blood vessels, thereby increasing the blood supply to ischemic organs and tissues. FORWARD LOOKING STATEMENTS This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or f uture business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of VT dru g candidates, market acceptance of VT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage, and financial performance. Additionally, until VT is cash flow positive from operations, the Company is dependent upon raising capital to f und its operations and meet its obligations as they come due. There can be no assurance that VT will be able to raise the necessary capital when needed. SOURCE: Venturis Therapeutics, Inc.

The release as fetched from its publisher. venturistherapeutics.com ↗